Effectiveness of a Schema Therapy on Anxiety in Patients With Multiple Sclerosis
Effectiveness of a Schema Therapy on Anxiety in Patients With Multiple Sclerosis
It is a multicentric randomized and controlled study comparing a Scheme therapy program
 versus local practice in RRMS patients with anxiety. Patients will assist to twenty
 once-weekly group sessions with a 6-month follow up after the end of the programme. The main
 criteria is the impact of schema therapy on anxiety evaluated by the questionnaires at the
 end of the program and at the end of the 6-month follow-up.
A parallel arm randomized controlled trial comparing a group receiving Scheme Therapy plus
 current usual practice versus a group receiving current local practice only. The trial will
 take place in KASHANI Hospital (in Isfahan).Recruitment of the participants will be
 identified and recruited by the neurologists of the hospitals who take part in the programme,
 when they come for a medical examination.

 After giving their informed consent, the patients will be entered onto the trial database and
 randomized to either the schema therapy or control using software allocated The intervention
 is the schema therapy focuses on the management of anxiety and is based on self-efficacy,
 self-management . It consists of 20 once-weekly sessions of 90 minutes (with a 15 Min break),
 with homework activities between the sessions. It is designed for groups of 8 people and will
 be delivered by two psychologists. The programme is standardized: Power Points presentations
 support each session and a detailed therapist manual and companion patient workbook accompany
 the programme.

 For the ST group an evaluation will be administered pretest and post-test six months after
 the end of the schema therapy programme and at the same times for those in the control group.
 Socio-demographic and medical data, age, sex, level of education, marital status, number of
 children and professional status; date of diagnosis, disease type, level of disability (EDSS,
 Kurtzke, 1983) and information on relapses and treatments, are evaluated. The main criteria
 is the impact of schema therapy on anxiety evaluated by the BAI (beck anxiety inventory ) and
 level of cortisol at 6 month after the start program . Secondary criteria are: impact on the
 psychological dimensions assessed by Hospital Anxiety and Depression Scale (HADS), intensity
 of fatigue assessed by Fatigue Severity Scale (FSS), sleep quality evaluated by the
 Pittsburgh Sleep Quality Index(PSQI) depression by BDI (beck depression inventory ) and
 quality of life evaluated by (Multiple sclerosis impact scale) MSIS29.
Inclusion Criteria:

 -  subject has relapsing remitting MS

 -  anxiety (score >26 at the BAI scale)

 -  history of psychotic disorders

 -  history of cognitive deficiency

 -  use anti-depressant in the past 3 months

 -  history of relapse in the past 3 month

 -  expanded Disability Status Scale score less than 6

 -  ability reading and writing Persian

 -  Non hospitalized

 Exclusion Criteria:

 -  history of psychotic disorders

 -  history of cognitive deficiency

 -  use anti-depressant in the past 3 months

 -  history of relapse in the past 3 month